การทบทวนวรรณกรรมอย่างเป็นระบบ การวิเคราะห์ต้นทุนประสิทธิภาพการฉีดวัคซีนป้องกันไข้หวัดใหญ่ และการวิเคราะห์ต้นทุนประสิทธิภาพของการฉีดวัคซีนเปรียบเทียบระหว่าง 3 และ 4 สายพันธุ์ ตั้งแต่ปี 2013-2017
Article Sidebar
เผยแพร่แล้ว:
มิ.ย. 7, 2019
คำสำคัญ:
วัคซีนไข้หวัดใหญ่ ราคาต่อประสิทธิผล
Main Article Content
บทคัดย่อ
วัตถุประสงค์ :จุดประสงค์ของการทบทวนการทบทวนวรรณกรรมอย่างเป็นระบบเพื่อศึกษาการวิเคราะห์ต้นทุนประสิทธิภาพ การฉีดวัคซีนป้องกันไข้หวัดใหญ่ในการป้องกันการเกิดโรคไข้หวัดใหญ่และผลกระทบที่เกิดขึ้น
วัสดุและวิธีการ :จากการสืบค้นเกี่ยวกับวัคซีนไข้หวัดใหญ่ 25 บทความ และการเปรียบเทียบประสิทธิภาพการฉีดวัคซีน ไข้หวัดใหญ่ 3 สายพันธุ์และ 4 สายพันธุ์ จำนวน 10 บทความ
ผลการศึกษา :พบว่าส่วนใหญ่การฉีดวัคซีนไข้หวัดใหญ่ทำให้ประหยัดค่าใช้จ่ายในการรักษาพยาบาลทั้งในมุมมองของ ส่วนบุคคลและสังคม
สรุป : การฉีดวัคซีนไข้หวัดใหญ่ 4 สายพันธุ์ มีประสิทธิภาพในการป้องกันควบคุมโรคได้ดีกว่า ดังนั้นในสภาวะเศรษฐกิจปัจจุบัน ที่จำเป็นต้องใช้ทรัพยากรอย่างจำกัด หากต้องเลือกวัคซีน ควรเลือกฉีดวัคซีนไข้หวัดใหญ่ 4 สายพันธุ์ เพื่อป้องกันโรคและ ควบคุมโรคอันจะเป็นประโยชน์สูงสุด
Article Details
รูปแบบการอ้างอิง
Ngamsanga, S. (2019). การทบทวนวรรณกรรมอย่างเป็นระบบ การวิเคราะห์ต้นทุนประสิทธิภาพการฉีดวัคซีนป้องกันไข้หวัดใหญ่ และการวิเคราะห์ต้นทุนประสิทธิภาพของการฉีดวัคซีนเปรียบเทียบระหว่าง 3 และ 4 สายพันธุ์ ตั้งแต่ปี 2013-2017. แพทยสารทหารอากาศ, 65(1), 1–11. สืบค้น จาก https://he02.tci-thaijo.org/index.php/rtafmg/article/view/193162
ประเภทบทความ
นิพนธ์ต้นฉบับ
บทความที่ได้รับการตีพิมพฺเป็นลิขสิทธิ์ของวารสาร
เอกสารอ้างอิง
1. Health De Influenza. The Green Book. Chapter 19 2012; Available from: https://www.wp.dh.gov.uk/
immunisation/files/2012/07/Green.
2. Pitman RJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007;
54(6):530-8.
3. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28 Suppl 4:D45-53.
4. Irving SA. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a
defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012; 6(1):37-43.
5. Fields BN, Knipe DM, Howley PM, Fields virology. 2013, Philadelphia: Wolters Kluwer Health/Lippincott Williams
& Wilkins.
6. Thompson WW. Estimates of US influenza-associated deaths made using four different methods. Influenza Other
Respir Viruses 2009;3(1):37-49.
7. Zhou, H. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.
Clin Infect Dis, 2012;54(10):1427-36.
8. Galvani AP, Reluga TC, Chapman GB. Longstanding influenza vaccination policy is in accord with individual
self-interest but not with the utilitarian optimum. Proc Natl Acad Sci U S A, 2007;104(13):5692-7.
9. Wu BF, Fu F, Wang L. Imperfect Vaccine Aggravates the Long-Standing Dilemma of Voluntary Vaccination. PLoS
ONE 2011;6(6):e20577.
10. Plotkin S. Herd immunity: a rough guide. 2001;Vol. 52:911-916.
11. Myers LB, Goodwin R. Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC Public
Health 2011;11(1):15.
12. Eastwood K. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust,
2010;192(1):33-6.
13. Liao Q. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong
Kong: a longitudinal study. PLoS One 2011;6(3):e17713.
14. Streefland PH. Public doubts about vaccination safety and resistance against vaccination. Health Policy
2001;55(3):159-72.
15. Francois, G., et al., Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J
2005;24(11):953-61.
16. Lau, J.T.F., et al., Acceptability of A/H1N1 vaccination during pandemic phase of influenza A/H1N1 in Hong
Kong: population based cross sectional survey. BMJ 2009;339-2.
17. Ambrose, C.S. and M.J. Levin, The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother
2012;8(1):81-8.
18. Skowronski DM. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel
surveillance network in Canada, 2006-2007. J Infect Dis 2009;199(2):168-79.
19. Beran J.Challenge of conducting a placebocontrolled randomized efficacy study for influenza vaccine in a season
with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009;9:2-5.
20. Skowronski, D.M., et al., Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel
physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine
2007;25(15):2842-51.
21. Frey S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy
adults. Clin Infect Dis 2010;51(9):997-1004.
22. Belongia EA. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and
final results. Vaccine 2011;29(38):6558-63.
23. Heinonen S. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational
cohort study. Lancet Infect Dis 2011;11(1):23-9.
24. Janjua NZ. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada’s sentinel surveillance system:
cross-protection against major and minor variants. J Infect Dis 2012;205(12):1858-68.
25. Zwahlen M. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation, 2nd Ed. Haddix A,
Teutsch SM, Corso PS. Oxford: Oxford University Press 2003.264-70.
26. Szucs T. Cost-benefits of vaccination programmes. Vaccine 2000;18 Suppl 1:S49-51.
27. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales:
Results from a dynamic transmission model. Vaccine 2013;31(6):927-42.
28. Chen SC, Liao CM. Cost-effectiveness of influenza control measures: a dynamic transmission model-based
analysis. Epidemiol Infect 2013;141(12):2581-94.
29. Wang IK. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine
2013;31(4):718-24.
30. Newall AT. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and
seasonal variability. Pharmacoeconomics 2013;31(8):693-702.
31. Kelso JK, Halder N, Milne GL. Vaccination strategies for future influenza pandemics: a severity-based cost
effectiveness analysis. BMC Infect Dis 2013;13:81-5.
32. Skene KJ. A marginal benefit approach for vaccinating influenza “superspreaders”. Med Decis Making
2014;34(4):536-49.
33. Halder N, Kelso JK, Milne GJ. A model-based economic analysis of pre-pandemic influenza vaccination cost-
effectiveness. BMC Infectious Diseases 2014;14(1):266-70.
34. Zhou L. Cost-Effectiveness of Alternative Strategies for Annual Influenza Vaccination among
Children Aged 6 Months to 14 Years in Four Provinces in China. PLOS ONE 2014; 9(1):e87590.
35. Yamin D, Balicer RD, Galvani AP. Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
Vaccine 2014;32(33):4198-205.
36. Gregg M. Economic evaluation of an influenza immunization strategy of healthy children. Int J Technol Assess
Health Care 2014;30(4):394-9.
37. Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory
analysis of the vaccine efficacy required. Vaccine 2014;32(12):1323-5.
38. Yoo BK. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program–
Results from a randomized controlled trial. BMC Health Services Research 2015;15:511-20.
39. Chit A. Expected cost effectiveness of highdose trivalent influenza vaccine in US seniors. Vaccine
2015;33(5):734-41.
40. Baguelin M. Extending the elderly- and riskgroup programme of vaccination against seasonal influenza in England
and Wales: a cost-effectiveness study. BMC Med 2015;13:236-40.
41. Lee BY. Quantifying the economic value and quality of life impact of earlier influenza vaccination. Med Care
2015;53(3):218-29.
42. Meeyai A. Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. PLOS Medicine
2015;12(5):e1001829.
43. Thorrington D, Jit M, Eames K. Targeted vaccination in healthy school children - Can primary school vaccination
alone control influenza? Vaccine 2015;33(41):5415-24.
44. Smith KJ. Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S. Am J Prev Med
2016;50(5):600-8.
45. Akin L. Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in
Turkey. PLoS One 2016;11(6):e0157657.
46. Xu J. Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women. Vaccine
2016;34(27):3149-55.
47. Becker DL. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes
compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother
2016;12(12):3036-42.
48. Thorrington D. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med
2017;15(1):166-70.
49. Kittikraisak W. Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ?60
months of age. PLoS ONE 2017;12(8):e0183391.
50. Orenstein EW. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS
One 2017;12(2):e0171499.
51. Hodgson D. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in
England and Wales: a modelling and cost-effectiveness analysis. The Lancet Public Health;2(2):e74-e81.
52. You, J.H., W.K. Ming, and P.K. Chan, Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent
influenza vaccine for elderly in Hong Kong. BMC Infect Dis, 2014.14:p. 618.
53. Blommaert A. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and
persons with underlying illnesses in Belgium. Vaccine 2014; 32(46):6075-83.
54. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent
influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One
2014;9(6):e98437.
55. Thommes EW. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention:
a dynamic modeling study of Canada and the United Kingdom. BMC Infectious Diseases 2015;15(1):465-70.
56. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision
analysis. Hum Vaccin Immunother 2015;11(3):564-71.
57. de Boer PT. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value
Health 2016;19(8):964-75.
58. Dolk C. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based
Dynamic Transmission Model. Pharmacoeconomics 2016;34(12):1299-308.
59. Nagy L. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in
Finland. Pharmacoeconomics 2016;34:939-51.
60. Uhart M. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza
vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother 2016;12(9):2259-68.
61. Raviotta JM. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J
Am Geriatr Soc 2016;64(10):2126-31.
immunisation/files/2012/07/Green.
2. Pitman RJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007;
54(6):530-8.
3. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28 Suppl 4:D45-53.
4. Irving SA. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a
defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012; 6(1):37-43.
5. Fields BN, Knipe DM, Howley PM, Fields virology. 2013, Philadelphia: Wolters Kluwer Health/Lippincott Williams
& Wilkins.
6. Thompson WW. Estimates of US influenza-associated deaths made using four different methods. Influenza Other
Respir Viruses 2009;3(1):37-49.
7. Zhou, H. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.
Clin Infect Dis, 2012;54(10):1427-36.
8. Galvani AP, Reluga TC, Chapman GB. Longstanding influenza vaccination policy is in accord with individual
self-interest but not with the utilitarian optimum. Proc Natl Acad Sci U S A, 2007;104(13):5692-7.
9. Wu BF, Fu F, Wang L. Imperfect Vaccine Aggravates the Long-Standing Dilemma of Voluntary Vaccination. PLoS
ONE 2011;6(6):e20577.
10. Plotkin S. Herd immunity: a rough guide. 2001;Vol. 52:911-916.
11. Myers LB, Goodwin R. Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC Public
Health 2011;11(1):15.
12. Eastwood K. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust,
2010;192(1):33-6.
13. Liao Q. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong
Kong: a longitudinal study. PLoS One 2011;6(3):e17713.
14. Streefland PH. Public doubts about vaccination safety and resistance against vaccination. Health Policy
2001;55(3):159-72.
15. Francois, G., et al., Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J
2005;24(11):953-61.
16. Lau, J.T.F., et al., Acceptability of A/H1N1 vaccination during pandemic phase of influenza A/H1N1 in Hong
Kong: population based cross sectional survey. BMJ 2009;339-2.
17. Ambrose, C.S. and M.J. Levin, The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother
2012;8(1):81-8.
18. Skowronski DM. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel
surveillance network in Canada, 2006-2007. J Infect Dis 2009;199(2):168-79.
19. Beran J.Challenge of conducting a placebocontrolled randomized efficacy study for influenza vaccine in a season
with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009;9:2-5.
20. Skowronski, D.M., et al., Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel
physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine
2007;25(15):2842-51.
21. Frey S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy
adults. Clin Infect Dis 2010;51(9):997-1004.
22. Belongia EA. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and
final results. Vaccine 2011;29(38):6558-63.
23. Heinonen S. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational
cohort study. Lancet Infect Dis 2011;11(1):23-9.
24. Janjua NZ. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada’s sentinel surveillance system:
cross-protection against major and minor variants. J Infect Dis 2012;205(12):1858-68.
25. Zwahlen M. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation, 2nd Ed. Haddix A,
Teutsch SM, Corso PS. Oxford: Oxford University Press 2003.264-70.
26. Szucs T. Cost-benefits of vaccination programmes. Vaccine 2000;18 Suppl 1:S49-51.
27. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales:
Results from a dynamic transmission model. Vaccine 2013;31(6):927-42.
28. Chen SC, Liao CM. Cost-effectiveness of influenza control measures: a dynamic transmission model-based
analysis. Epidemiol Infect 2013;141(12):2581-94.
29. Wang IK. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine
2013;31(4):718-24.
30. Newall AT. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and
seasonal variability. Pharmacoeconomics 2013;31(8):693-702.
31. Kelso JK, Halder N, Milne GL. Vaccination strategies for future influenza pandemics: a severity-based cost
effectiveness analysis. BMC Infect Dis 2013;13:81-5.
32. Skene KJ. A marginal benefit approach for vaccinating influenza “superspreaders”. Med Decis Making
2014;34(4):536-49.
33. Halder N, Kelso JK, Milne GJ. A model-based economic analysis of pre-pandemic influenza vaccination cost-
effectiveness. BMC Infectious Diseases 2014;14(1):266-70.
34. Zhou L. Cost-Effectiveness of Alternative Strategies for Annual Influenza Vaccination among
Children Aged 6 Months to 14 Years in Four Provinces in China. PLOS ONE 2014; 9(1):e87590.
35. Yamin D, Balicer RD, Galvani AP. Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
Vaccine 2014;32(33):4198-205.
36. Gregg M. Economic evaluation of an influenza immunization strategy of healthy children. Int J Technol Assess
Health Care 2014;30(4):394-9.
37. Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory
analysis of the vaccine efficacy required. Vaccine 2014;32(12):1323-5.
38. Yoo BK. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program–
Results from a randomized controlled trial. BMC Health Services Research 2015;15:511-20.
39. Chit A. Expected cost effectiveness of highdose trivalent influenza vaccine in US seniors. Vaccine
2015;33(5):734-41.
40. Baguelin M. Extending the elderly- and riskgroup programme of vaccination against seasonal influenza in England
and Wales: a cost-effectiveness study. BMC Med 2015;13:236-40.
41. Lee BY. Quantifying the economic value and quality of life impact of earlier influenza vaccination. Med Care
2015;53(3):218-29.
42. Meeyai A. Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. PLOS Medicine
2015;12(5):e1001829.
43. Thorrington D, Jit M, Eames K. Targeted vaccination in healthy school children - Can primary school vaccination
alone control influenza? Vaccine 2015;33(41):5415-24.
44. Smith KJ. Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S. Am J Prev Med
2016;50(5):600-8.
45. Akin L. Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in
Turkey. PLoS One 2016;11(6):e0157657.
46. Xu J. Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women. Vaccine
2016;34(27):3149-55.
47. Becker DL. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes
compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother
2016;12(12):3036-42.
48. Thorrington D. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med
2017;15(1):166-70.
49. Kittikraisak W. Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ?60
months of age. PLoS ONE 2017;12(8):e0183391.
50. Orenstein EW. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS
One 2017;12(2):e0171499.
51. Hodgson D. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in
England and Wales: a modelling and cost-effectiveness analysis. The Lancet Public Health;2(2):e74-e81.
52. You, J.H., W.K. Ming, and P.K. Chan, Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent
influenza vaccine for elderly in Hong Kong. BMC Infect Dis, 2014.14:p. 618.
53. Blommaert A. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and
persons with underlying illnesses in Belgium. Vaccine 2014; 32(46):6075-83.
54. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent
influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One
2014;9(6):e98437.
55. Thommes EW. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention:
a dynamic modeling study of Canada and the United Kingdom. BMC Infectious Diseases 2015;15(1):465-70.
56. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision
analysis. Hum Vaccin Immunother 2015;11(3):564-71.
57. de Boer PT. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value
Health 2016;19(8):964-75.
58. Dolk C. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based
Dynamic Transmission Model. Pharmacoeconomics 2016;34(12):1299-308.
59. Nagy L. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in
Finland. Pharmacoeconomics 2016;34:939-51.
60. Uhart M. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza
vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother 2016;12(9):2259-68.
61. Raviotta JM. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J
Am Geriatr Soc 2016;64(10):2126-31.
